Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20160314003
TCTR20160314003
Completed
Phase 1

Intratympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-induced Ototoxicity: Double Blind Randomized Clinical Trial

Student Research Committee0 sites114 target enrollmentMarch 14, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionshearing impairmentHearing LossIntratympanic InjectionDexamethasoneAcetylcysteine

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
hearing impairment
Sponsor
Student Research Committee
Enrollment
114
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 14, 2016
End Date
December 1, 2014
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Student Research Committee

Eligibility Criteria

Inclusion Criteria

  • •first cycle of cisplatin therapy
  • •normal tympanogram type A
  • •normal microscopic examinations
  • •no history of head trauma, brain tumors, severe ear infection, ear surgery, ruptured eardrums, meningoencephalitis, acoustic trauma and cranial radiation

Exclusion Criteria

  • •Patients in the end stages of cancers or taking other ototoxic drugs

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Injection of N-acetylcysteine through the eardrum to reduce hearing loss related to Cisplatin chemotherapy.OtotoxicityMedDRA version: 20.0Level: PTClassification code 10033109Term: OtotoxicitySystem Organ Class: 10013993 - Ear and labyrinth disordersTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-004463-44-BECHU Saint Pierre86
Recruiting
Phase 1
Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.Ototoxic Hearing Loss
NCT04291209Sunnybrook Health Sciences Centre80
Enrolling By Invitation
Phase 3
Intravenous N-acetyl-cysteine (NAC) for Prevention of Post-embolization Syndrome in Hepatocellular CarcinomaHepatocellular CarcinomaTransarterial Chemoembolization
TCTR20150313002Faculty of Medicine, Thammasat University80
Recruiting
Phase 3
Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgeryRenal Impairment in cardiac surgeryRenal and Urogenital - Other renal and urogenital disordersCardiovascular - Other surgery
ACTRN12606000088549Prince of Wales Hospital200
Terminated
Phase 4
Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced OtotoxicityOtotoxic Hearing LossOtotoxic Hearing Loss, BilateralOtotoxicityTinnitus
NCT04226456Centre Hospitalier Universitaire Saint Pierre19